Cardiol Therapeutics | WebDisclosure

PRESS RELEASE

published on 04/23/2025 at 15:24, 1 year 3 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates recommendation for Cardiol Therapeutics Inc, maintaining Buy rating and USD 8.50 target price. CardiolRxT phase III study enrollment for recurrent pericarditis (RP) shows promise for FDA approval

FDA Approval Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating CardiolRxT
BRIEF

published on 11/22/2024 at 11:11, 1 year 8 months ago

Cardiol Therapeutics obtient une note d'achat suite à des résultats d'essais prometteurs

Essais Cliniques Acheter Une Note CardiolRx Thérapeutique Cardiol Efficacité Des Médicaments
BRIEF

published on 11/22/2024 at 11:11, 1 year 8 months ago

Cardiol Therapeutics Secures Buy Rating Amid Promising Trial Results

Clinical Trials BUY Rating Cardiol Therapeutics CardiolRx Drug Efficacy
PRESS RELEASE

published on 11/22/2024 at 11:06, 1 year 8 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): BUY
First Berlin Equity Research reaffirms BUY rating for Cardiol Therapeutics Inc. with USD8.50 price target based on positive final data for CardiolRx in treating recurrent pericarditis

Cardiol Therapeutics Inc First Berlin Equity Research BUY Rating Reaffirmed CardiolRx
BRIEF

published on 10/28/2024 at 15:51, 1 year 9 months ago

Cardiol Therapeutics lance un essai clinique de phase II/III pour la péricardite récurrente

Essai Clinique CardiolRx Péricardite Récurrente Thérapeutique Cardiol Essai MAVERIC-2
BRIEF

published on 10/28/2024 at 15:51, 1 year 9 months ago

Cardiol Therapeutics Initiates Phase II/III Clinical Trial for Recurrent Pericarditis

Clinical Trial Cardiol Therapeutics CardiolRx Recurrent Pericarditis MAVERIC-2 Trial
PRESS RELEASE

published on 10/28/2024 at 15:46, 1 year 9 months ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research updates BUY recommendation for Cardiol Therapeutics Inc., initiating phase II/III clinical trial for recurrent pericarditis treatment with CardiolRx

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Clinical Trial Pericarditis Treatment
BRIEF

published on 06/14/2024 at 14:57, 2 years 1 month ago

Cardiol Therapeutics Inc reçoit une note « d'achat » mise à jour de la part de First Berlin Equity Research

Acheter Une Note CardiolRx Cardiol Thérapeutique Péricardite Récurrente Étude De Phase II
BRIEF

published on 06/14/2024 at 14:57, 2 years 1 month ago

Cardiol Therapeutics Inc Receives Updated 'Buy' Rating from First Berlin Equity Research

BUY Rating Cardiol Therapeutics CardiolRx Recurrent Pericarditis Phase II Study
PRESS RELEASE

published on 06/14/2024 at 14:52, 2 years 1 month ago

Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy
First Berlin Equity Research increases Cardiol Therapeutics Inc's price target to USD8.50 in Buy recommendation after positive results from phase II trial of CardiolRx for recurrent pericarditis treatment

Cardiol Therapeutics Inc First Berlin Equity Research Buy Recommendation Phase II Trial CardiolRx

Published on 08/07/2026 at 14:17, 3 hours 31 minutes ago

NuRAN Wireless Increases Series A Preferred Share Financing to C$7.6 Million and Announces Debt Settlements
Published on 08/07/2026 at 13:00, 4 hours 48 minutes ago

Gold Terra Announces Start of Drilling on the Campbell Shear Northern Zone 103N Extension to Expand 2026 MRE of Inferred 595,000 Ounces, Con Mine, Yellowknife, NWT
Published on 08/07/2026 at 00:45, 17 hours 3 minutes ago

NXT Energy Solutions Announces Second Quarter 2026 Results
Published on 08/06/2026 at 23:15, 18 hours 33 minutes ago

LNG Energy Group Announces Issuance of Second Partial Revocation Order and Further Details on Private Placement Financing
Published on 08/06/2026 at 22:15, 19 hours 33 minutes ago

Biomind Labs Announces Listing on the Canadian Securities Exchange and the Delisting From the Cboe Canada

View all ACCESSWIRE

Published on 08/07/2026 at 17:34, 13 minutes ago

Fuller, Smith & Turner PLC: Director/PDMR Shareholdings
Published on 08/07/2026 at 16:51, 56 minutes ago

Issue of Equity
Published on 08/07/2026 at 16:34, 1 hour 13 minutes ago

Net Asset Value(s)
Published on 08/07/2026 at 15:39, 2 hours 8 minutes ago

Predictiv AI Inc. Hires Aktien Media for Internet Advertising Services
Published on 08/07/2026 at 15:16, 2 hours 31 minutes ago

Announcement pursuant to Art. 5 para 1 of Regulation (EU) No. 596/2014 in conjunction with Art. 2 para 1 of the Delegated Regulation (EU) 2016/1052 of the Commission

View all EQS

Published on 08/07/2026 at 17:35, 13 minutes ago

Production du 1ier semestre 2026
Published on 08/07/2026 at 15:36, 2 hours 11 minutes ago

NRJ Group - Information relative aux droits de vote au 31.07.2026 (French & English)
Published on 08/07/2026 at 08:30, 9 hours 18 minutes ago

Disclosure of shares outstanding and voting rights - 07.08.2026
Published on 08/07/2026 at 08:30, 9 hours 18 minutes ago

Déclaration nombre d'actions et droits de vote - 07.08.2026
Published on 08/06/2026 at 18:26, 23 hours 22 minutes ago

Air Liquide voting rights as of July 31st 2026

View all LES ECHOS COMFI WIRE

News